Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system with demyelination, axon damage, and paralysis. Induction of mixed chimerism with allogeneic donors has been shown to not cause graft-versus-host disease (GVHD) in animal models and humans. We have reported that induction of MHC-mismatched mixed chimerism can cure autoimmunity in autoimmune NOD mice, but this approach has not yet been tested in animal models of MS, such as experimental autoimmune encephalomyelitis (EAE). Here, we report that MHC-mismatched mixed chimerism with C57BL/6 (H-2 
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− thymocytes. Thymectomy leads to loss of prevention of EAE relapse by induction of mixed chimerism, although there is a dramatic expansion of host-type Treg cells in the lymph nodes. These results indicate that induction of MHC-mismatched mixed chimerism can restore thymic negative selection of autoreactive CD4 + T cells, augment production of Foxp3 + Treg, and cure EAE.
mixed chimerism | autoimmunity | experimental autoimmune encephalomyelitis | Foxp3 regulatory T cells | radiation-free conditioning regimen M ultiple sclerosis (MS) is an inflammatory autoimmune disease that attacks the central nervous system, resulting in demyelination, damage to neuronal cells, and paralysis (1) (2) (3) . MS patients have quantitative and qualitative defects in peripheral Foxp3
+ Treg cells (4) (5) (6) . Different from other autoimmune diseases, such as autoimmune type-1 diabetes and systemic lupus, MS often manifests with a progressive pattern of remission and relapse (1) . Remission is associated with an increase of peripheral Treg cells in humans and an enhanced suppressive capacity of Treg cells in mouse models; however, effective Treg therapy has not been reported (7, 8) .
Induction of mixed chimerism with HLA-matched allogeneic hematopoietic cell transplantation (HCT) has been shown to provide transplantation immune tolerance without causing any signs of graft-versus-host disease (GVHD) in humans (9) . Even so, HLA-matched mixed chimerism has been unable to reverse systemic lupus (9) . However, induction of MHC-mismatched mixed chimerism is able to reverse autoimmunity in mouse models (10, 11) . In particular, we have reported that induction of mixed chimerism under a radiation-free anti-CD3/CD8 conditioning regimen reversed autoimmune type 1 diabetes (T1D) and systemic lupus (12) (13) (14) (15) (16) (17) (18) (19) . Induction of MHC-mismatched mixed chimerism can restore central tolerance by deleting autoreactive thymocytes with cross-reactivity (18) , and tolerize residual T cells in the periphery and delete preexisting and immature autoreactive B cells (15, 17) . Because of the lack of suitable anti-human CD3 and anti-human CD8 mAb, translation of this regimen has been hindered. To promote mixed chimerism as a curative therapy for autoimmune diseases, we have developed a radiation-free conditioning regimen that uses the clinically available reagents cyclophosphamide (CY), pentostatin (PT), and antithymocyte globulin (ATG), each of which has been used in the clinic before and after hematopoietic cell transplantation (HCT) for the conditioning of recipients and prevention of GVHD (20) .
In the current studies, we conditioned experimental autoimmune encephalomyelitis (EAE) SJL/J mice with a combination of low-dose CY, PT, and ATG and then transplanted the mice with CD4
+ T-depleted spleen and bone marrow (BM) cells from MHC-mismatched C57BL/6 donors. We found that induction of Significance Induction of MHC-or HLA-matched mixed chimerism does not cause graft-versus-host disease (GVHD) in animal models or humans, but matched mixed chimerism cannot reverse autoimmunity. MHC-mismatched mixed chimerism is required for reversal of autoimmunity. Here, we report that, using a clinically applicable conditioning regimen consisting of cyclophosphamide, pentostatin, and antithymocyte globulin, MHC-mismatched mixed chimerism is established in experimental autoimmune encephalomyelitis (EAE) mice without any signs of GVHD. The mismatched mixed chimerism reverses autoimmunity, augments myelin sheath regeneration, prevents EAE relapse, and cures the disease. The cure of EAE is associated with thymic deletion of host-type autoreactive T cells and increase of thymic production of host-type Foxp3 + Treg cells. Thus, induction of HLA-mismatched mixed chimerism can be a curative therapy for progressive MS.
MHC-mismatched mixed chimerism was able to eliminate spinal cord tissue infiltration and augment regeneration of myelin sheath and cure EAE in mice that did not have axon damage.
Materials and Methods
SJL/J and C57BL/6 mice were purchased from The Jackson Laboratory. Mice were maintained in a pathogen-free room in the City of Hope (COH) Animal Resource Center. Experimental procedures were approved by the COH Institutional Animal Care and Use Committee (IACUC). ATG was purchased from Accurate Chemical, and CY and PT from Sigma. EAE induction and score, histology and immunohistochemistry, transmission electron microscopy, flow cytometry staining and analysis, T-cell proliferation assay, and statistical analysis were described in our previous publications (13, 21) (Fig. 1A) . The recipients conditioned with CY + PT or CY + ATG were used as controls. On day 0, recipients were transplanted with bone marrow (BM) cells (50 × ) donors. After HCT, the recipients were monitored for clinical signs of GVHD and checked for chimerism monthly by staining peripheral blood mononuclear cells (PBMNC) with anti-H-2 b mAb. We found that none (0/6) of the recipients conditioned with CY + PT or CY + ATG alone developed chimerism, that is, no donor cell engraftment at all (Fig. 1B) .
In contrast, 71% (25/35) of recipients conditioned with CY + PT + ATG developed stable mixed chimerism, 17% (6/35) developed complete mixed chimerism, 8.5% (3/35) developed transient mixed chimerism, and 2.8% (1/35) had no engraftment (Fig. 1B) . At the experimental endpoint (75 d after HCT), the stable mixed chimeras did not show any signs of GVHD, and their tissues of skin, salivary gland, lung, and liver appeared to be the same as that of mice given conditioning alone (Fig. 1C) . The mixed chimerism status was also confirmed by the coexistence of donor and host-type T, B, and myeloid cells in the blood, spleen, thymus, and BM (Fig. S1 ). These results indicate that conditioning with CY + PT + ATG together are required for induction of stable mixed chimerism when transplanting BM and CD4 − -SPL cells from MHC-mismatched donors.
Induction of Mixed Chimerism Prevents EAE Relapse, Augments Myelin
Sheath Regeneration, and Prevents Axon Damage. SJL/J mice were induced to develop EAE as described in SI Materials and Methods. At the remission following first disease onset, the mice were conditioned and transplanted with C57BL/6 donor BM transplants to induce mixed chimerism. The EAE mice without treatment (model control) or treated with conditioning alone had relapses ∼2 wk later, and there was no significant difference in clinical disease scores between the two groups ( Fig. 2A) . In contrast, the mixed chimeric EAE mice showed no relapse and appeared to be healthy (P < 0.01, Fig. 2A ). Further, by fast blue staining, we compared the myelin sheath in EAE mice before conditioning, and with or without induction of mixed chimerism at 75 d after HCT. Compared with normal spinal cord tissue, there was ∼10% area of demyelination in the mice before conditioning, and as time went on, the model control mice and the conditioning-alone mice had ∼15% area of demyelination; in contrast, the mixed chimeras showed no demyelination at all (P < 0.01, Fig. 2 B and C). In addition, analysis with EM showed that there were demyelinated axons before conditioning, and there were not only demyelinated axons but also destroyed axons in the model control mice and conditioning-alone mice. In contrast, there were no damaged axons or demyelination in the tissues of mixed chimeras (Fig. 2D) . These results indicate that induction of mixed chimerism can prevent axon damage and augment myelin regeneration.
Induction of Mixed Chimerism Reverses Autoimmunity and Eliminates
Lymphocyte Infiltration in Spinal Tissue. Because EAE is mediated by myelin peptide reactive T cells (3), we measured the autoreactivity of host-type CD4 + T cells in the mixed chimeras, and CD4 + T cells from normal mice, untreated EAE mice, or conditioning-treated EAE mice were used as control. CD4 + T cells from control EAE mice proliferated actively in response to stimulation by myelin peptide-loaded DCs. In contrast, host-type CD4 + T cells from the mixed chimeras had significantly reduced proliferation compared with control CD4 + T cells (P < 0.01), which was similar to CD4 + T cells from normal mice (P > 0.1, Fig. 3A) . Consistently, whereas there was severe infiltration in the spinal tissues of untreated or conditioning-treated EAE mice, there was no infiltration in the tissue of mixed chimeras, which appeared identical to normal tissue (Fig. 3B) . It was reported that ectopic lymphoid tissues consisting of collagen I, T, and B cells occurs in chronic EAE mice (22) . We observed ectopic lymphoid tissues in the spinal tissues of untreated or conditioning-treated EAE mice, but not in the tissues of mixed chimeric mice (Fig. 3C) . Finally, infiltrating CD4 + T, B, and macrophages in the spinal cord tissues of EAE mice were eliminated in the mixed chimeras as judged by flow cytometry analysis of infiltrating cells (P < 0.001, Fig.  3D ). These results demonstrate that induction of mixed chimerism with MHC-mismatched donor BM cells can eliminate tissue inflammation of EAE. + T cells in the spleen and LN (P < 0.01), but the percentage of Th17 was still significantly higher than normal mice (P < 0.01, Fig. 4A ), and conditioning alone did not prevent EAE relapse (Fig. 2A) . Compared with EAE mice treated with conditioning alone, induction of mixed chimerism significantly reduced the percentage of host-type Th17 in the spleen and LN, especially in LN (P < 0.01, Fig. 4A ). Interestingly, compared with untreated EAE mice, conditioning alone or induction of mixed chimerism did not significantly change the percentage of IFN-γ +
CD4
+ Th1 cells in the LN, although it slightly reduced the percentage of T cells in the spleen (Fig. 4A) (Fig. 4C) . Surprisingly, induction of mixed chimerism increased Treg cells by ∼eightfold among CD4
+ thymocytes and by ∼20-fold among CD4 +
CD8
+ thymocytes, compared with EAE mice treated with conditioning alone (P < 0.01, Fig. 4C ). In addition, the host-type CD4 +
+ thymocytes were markedly reduced compared with that of recipients given conditioning alone (P < 0.01, Fig. 4C ).
Next, we measured the percentage of Foxp3 + cells among donor-type CD4 + T cells in the mixed chimeric EAE mice, using the normal donor mice as control. Induction of mixed chimerism did not increase the percentage of donor-type CD4
+

Foxp3
+ Treg cells among donor-type T cells in the spleen, spinal draining LN, or CD4 +
CD8
+ thymocytes of the mixed chimeras (P > 0.1), although there was an significant increase among CD4 +
− donortype thymocytes (P < 0.05, Fig. S2 ). There was no significant difference in the percentage of donor-type CD4 +
+ thymocytes either (Fig. S2 ). In addition, we observed that induction of mixed chimerism with the same conditioning and with C57BL/6 donor transplants in the normal SJL/J mice without induction of EAE did not increase the percentage of CD4
+
Foxp3
+ Treg cells among hosttype T cells in the spleen or spinal draining LN, or among host-type CD4 +
CD8
+ thymocytes (Fig. S3) . Similarly, induction of mixed chimerism did not reduce the percentage of host-type CD4 + CD8 + thymocytes (Fig. S3) . Taken together, these results indicate that induction of mixed chimerism augments negative selection of Foxp3 
+ thymocytes and augments thymic generation of Foxp3 + Treg cells in EAE SJL/J mice.
Induction of Mixed Chimerism in Thymectomized Recipients Does Not
Prevent EAE Relapse but Reduces Its Severity. We evaluated the thymus' role in prevention of EAE by using thymectomized EAE mice. Adult thymectomized SJL/J mice were induced to develop EAE and then induced to develop mixed chimerism (Fig. S4) . Induction of mixed chimerism was not able to prevent relapse of EAE, although it was able to significantly reduce the disease severity (P < 0.01, Fig. 5A ). Compared with EAE mice given conditioning alone, induction of mixed chimerism only partially reduced demyelination (P < 0.05, Fig. 5 B and C) . Although induction of mixed chimerism appeared to reduce tissue infiltration, there was still obvious infiltration under the spinal cord membrane (Fig. 5D) (Fig. S5A) . However, the percentage of Foxp3 + Treg cells among CD45.1 + host-type CD4 + T cells in the spinal draining LN of mixed chimeras reached ∼40%, which was significantly higher than in recipients given conditioning alone (P < 0.05, Fig. S5B ). The percentage of Foxp3 + cells among CD45.2 + donor-type CD4 + T cells was ∼30% (Fig. S5B) . These results indicate that induction of mixed chimerism in thymectomized EAE mice can augment expansion of Foxp3 + Treg cells in the periphery, especially in the spinal draining LN, but the expansion of Treg cells is not sufficient to prevent autoimmune EAE.
Induction of Mixed Chimerism in Late-Stage EAE Mice Eliminates
Infiltration in Spinal Tissues but Does Not Cure Disease. Finally, we evaluated whether induction of mixed chimerism is able to reverse late-stage EAE. EAE mice with multiple relapses and persistent high clinical score (≥2.5) for more than 20 d were defined as late stage. The experiments were ended at 50 d after HCT following the mandate of the IACUC. Compared with conditioning alone, induction of mixed chimerism only prevented the worsening of the disease (P < 0.01) but did not reverse the disease (Fig. S6A) . Although induction of mixed chimerism was able to clear tissue infiltration and significantly reduce demyelination, it was not able to adequately promote remyelination (Fig. S6 B-D) . This lack of recovery may be due to the damage of axon at this late stage, as suggested by holes in the white matter area (Fig. S6D ). thymocytes. In contrast, the MHC-mismatched mixed chimerism did not significantly change the percentage of donor-type DP thymocytes or Foxp3 + cells in the EAE SJL/J mice; the MHC-mismatched mixed chimerism did not change the percentage of donor-or host-type DP thymocytes or Foxp3
Discussion
+ cells in non-EAE control SJL/J mice. These results indicate that the marked reduction of DP thymocytes in the mixed chimeric EAE mice is unlikely to be due to the effect of stress hormones, as indicated in other studies (27) .
The mechanisms behind this observation remain unclear and may be explained by the following hypothesis: Although H-2 s SJL/J mice are susceptible to induction of EAE by antigen stimulation, the mice never spontaneously develop autoimmune EAE (28) . This phenomenon suggests that under the normal situation, the autoreactive T cells in the peripheral lymphoid tissues of SJL/J mice are tolerized, probably by regulatory T cells such as Foxp3 + Treg cells. After induction of EAE, peripheral autoreactive CD4 + T cells are expanded, infiltrate the CNS, and cause damage of myelin sheaths, axons, and eventually neurons (1) . At the same time, autoreactive T cells migrate into the thymus to damage medullary thymic epithelial cells (mTEC) and impair negative selection. Subsequently, more autoreactive T cells are generated and the disease is perpetuated. Autoreactive T cells can have dual TCRs and have cross-reactivity with mismatched MHC (29, 30) . Our recent publication has shown that MHC-mismatched mixed chimerism with a H-2 b transplant deletes cross-reactive autoreactive T cells with more than one TCR in H-2 g7 NOD mice in a donor-type APC-dependent manner (18) . Therefore, we theorize that H-2 b donor-type APCs in the thymic medullar mediate deletion of FoxP3 − autoreactive DP thymocytes in the mixed chimeric EAE mice on one hand and mediate relative expansion of the Foxp3 + DP thymocytes on the other hand, due to higher TCR affinity with mismatched MHC II. This hypothesis is consistent with previous reports that Foxp3 expression takes place in the late stages of DP thymocyte development, with stimulation by medium-high affinity to self-MHC-antigen complex (31) , and that Foxp3
+ thymocytes are more resistant to deletion (26, 31) . We should point out that, in addition to the increase of Foxp3 + DP thymocytes, the increase of Foxp3 + CD4 + CD8 − thymocytes in the mixed chimeric EAE mice can also result from recirculating CD4 + Treg cells from the periphery (32) . Further characterization of the Treg cells is warranted.
Our hypothesis also is consistent with clinical observations that autologous HCT that depletes preexisting autoreactive T cells and modulates the immune response in MS patients cannot provide a long-term cure of autoimmunity, although autologous HCT was able to effectively ameliorate clinical symptoms (33) . Moreover, this hypothesis is consistent with reports that MHCmatched allogeneic HCT with GVHD worsened clinical MS (34) . We would emphasize again that conditioning with lowdose CY, PT, and ATG as well as transplanting BM and lowdose CD4
+ T-depleting spleen cells, that is, low numbers of donor CD8 + T cells, induced mixed chimerism in most of the recipients. Mixed chimerism does not cause GVHD, and the key for MHC-mismatched mixed chimerism to restore central tolerance is the lack of GVHD; otherwise, GVHD itself damages thymic mTEC and worsens autoimmunity, as we have reported (35) . We should point out that this conditioning regimen can result in complete chimerism that has the potential to develop chronic GVHD when high numbers of donor CD8 + T cells are infused. Thus, infusion of appropriate numbers of donor CD8 + T cells can be an important factor for ensuring induction of mixed chimerism.
Induction of MHC-mismatched mixed chimerism appears unable to reverse autoimmunity in thymectomized EAE mice. We found that thymectomized EAE mice treated with conditioning alone had a higher percentage (∼25%) of Foxp3 + Treg cells among host-type CD4 + T cells compared with ∼10% in normal SJL/J mice. Induction of mixed chimerism further increased the Treg percentage to ∼40%. However, neither conditioning alone nor induction of MHC-mismatched mixed chimerism was able to prevent EAE relapse in the thymectomized mice. It is possible that thymectomy causes lymphopenia in which autoreactive T cells are resistant to Treg suppression (36) . Also, Foxp3 + Treg cells of MS patients have defects in both quantity and quality (5) . Thus, another possibility is that host-type Treg cells from de novo generation in the thymus of MHC-mismatched mixed chimeras may have better suppressor function.
MS is one of the most common chronic neurological diseases in young adults (37) , and these patients usually have thymic function. Thus, induction of mixed chimerism can be a potential long-term cure for young, newly diagnosed MS patients. In addition, we found that the progression of late-stage EAE was lessened, although mice with paralysis did not recover after induction of mixed chimerism. Thus, this therapy can still be beneficial to late-stage patients. In summary, induction of mixed chimerism under the radiation-free conditioning regimen of CY, PT, and ATG and with HLA mismatched or haploidentical donor transplants may represent a curative therapy for patients with highly active, progressing MS that is refractory to conventional MS therapies.
